Future research directions in pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 198, Issue 2, 2018, Pages 256-263

  Dela Cruz, Charles S ^a   Wunderink, Richard G ^b   Christiani, David C ^c,d   Cormier, Stephania A ^e   Crothers, Kristina ^f   Doerschuk, Claire M ^g   Evans, Scott E ^h   Goldstein, Daniel R ^i,j   Khatri, Purvesh ^k   Kobzik, Lester ^c   Kolls, Jay K ^l   Levy, Bruce D ^m   Metersky, Mark L ⁿ   Niederman, Michael S ^o   Nusrat, Roomi ^p   Orihuela, Carlos J ^q   Peyrani, Paula ^r   Prince, Alice S ^s   Ramírez, Julio A ^r   Ridge, Karen M ^b   Sethi, Sanjay ^t   Suratt, Benjamin T ^u   Sznajder, Jacob I ^b   Tsalik, Ephraim L ^v,w   Walkey, Allan J ^x   Yende, Sachin ^y,z   Aggarwal, Neil R ^aa   Caler, Elisabet V ^aa   Mizgerd, Joseph P ^x   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Department of Internal Medicine ^*  (United States)

^j UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^q University of Alabama at Birmingham   (United States)

^r University of Louisville School of Medicine   (United States)

^s University at Buffalo State University of New York ^*  (United States)

^t UNIVERSITY AT BUFFALO   (United States)

^u UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^v DURHAM VA HEALTH CARE SYSTEM   (United States)

^w DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^z VETERANS AFFAIRS MEDICAL CENTER   (United States)

^aa DLD/NHLBI   (United States)

more..

Author keywords

Bacterial infection; Host response; Host susceptibility; Pneumonia; Viral infection

Indexed keywords

CONFERENCE PAPER; DISEASE PREDISPOSITION; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; PNEUMONIA; PRIORITY JOURNAL; RESEARCH PRIORITY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; BACTERIAL INFECTION; FEMALE; LUNG; MALE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; ORGANIZATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RESEARCH; UNITED STATES; VERY ELDERLY; VIRUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; CONGRESSES AS TOPIC; DISEASE SUSCEPTIBILITY; FEMALE; HOST MICROBIAL INTERACTIONS; HUMANS; LUNG; MALE; MIDDLE AGED; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); PNEUMONIA; RESEARCH REPORT; RESPIRATORY DISTRESS SYNDROME, ADULT; UNITED STATES; VIRUS DISEASES;

EID: 85048936786     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201801-0139WS     Document Type: Conference Paper

References (71)

1. GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017;17:1133–1161.
2. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al.; University of Louisville Pneumonia Study Group. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 2017;65:1806–1812.
3. Wallihan R, Ramilo O. Community-acquired pneumonia in children: current challenges and future directions. J Infect 2014;69(Suppl 1): S87–S90.
4. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al.; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53:e25–e76.
5. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005;294:2712–2719.
6. Boyd AR, Orihuela CJ. Dysregulated inflammation as a risk factor for pneumonia in the elderly. Aging Dis 2011;2:487–500.
7. Wong CK, Smith CA, Sakamoto K, Kaminski N, Koff JL, Goldstein DR. Aging impairs alveolar macrophage phagocytosis and increases influenza-induced mortality in mice. J Immunol 2017;199:1060–1068.
8. Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. Physiol Rev (In press)
9. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 2009;9:377–384.
10. Kang MJ, Lee CG, Lee JY, Dela Cruz CS, Chen ZJ, Enelow R, et al. Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice. J Clin Invest 2008;118:2771–2784.
11. Cohen AJ, Brauer M, Burnett R, Anderson HR, Frostad J, Estep K, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet 2017;389:1907–1918.
12. Kurt OK, Zhang J, Pinkerton KE. Pulmonary health effects of air pollution. Curr Opin Pulm Med 2016;22:138–143.
13. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med 2017;5:426–434.
14. Farne HA, Johnston SL. Immune mechanisms of respiratory viral infections in asthma. Curr Opin Immunol 2017;48:31–37.
15. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 2016;315:2284–2291.
16. Holtzman MJ, Byers DE, Alexander-Brett J, Wang X. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat Rev Immunol 2014;14:686–698.
17. Sajjan US. Susceptibility to viral infections in chronic obstructive pulmonary disease: role of epithelial cells. Curr Opin Pulm Med 2013; 19:125–132.
18. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010;16:118–122.
19. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 2015;70:984–989.
20. Vakil E, Evans SE. Viral pneumonia in patients with hematologic malignancy or hematopoietic stem cell transplantation. Clin Chest Med 2017;38:97–111.
21. Berenson CS, Kruzel RL, Eberhardt E, Dolnick R, Minderman H, Wallace PK, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax 2014;69:811–818.
22. Ubags ND, Stapleton RD, Vernooy JH, Burg E, Bement J, Hayes CM, et al. Hyperleptinemia is associated with impaired pulmonary host defense. JCI Insight 2016;1:e82101.
23. Neidich SD, Green WD, Rebeles J, Karlsson EA, Schultz-Cherry S, Noah TL, et al. Increased risk of influenza among vaccinated adults who are obese. Int J Obes 2017;41:1324–1330.
24. Zhang AJ, To KK, Li C, Lau CC, Poon VK, Chan CC, et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A (H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J Infect Dis 2013;207:1270–1280.
25. Suratt BT. Mouse modeling of obese lung disease: insights and caveats. Am J Respir Cell Mol Biol 2016;55:153–158.
26. Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med 2017;38:263–277.
27. Hayden LP, Cho MH, McDonald MN, Crapo JD, Beaty TH, Silverman EK, et al.; COPDGene Investigators. Susceptibility to childhood pneumonia: a genome-wide analysis. Am J Respir Cell Mol Biol 2017;56:20–28.
28. Zúñiga J, Buendía-Roldán I, Zhao Y, Jiménez L, Torres D, Romo J, et al. Genetic variants associated with severe pneumonia in A/H1N1 influenza infection. Eur Respir J 2012;39:604–610.
29. Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, et al.; ESICM/ECCRN GenOSept Investigators. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med 2015;3:53–60.
30. Quinton LJ, Mizgerd JP. Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling. Annu Rev Physiol 2015;77:407–430.
31. Chen K, Kolls JK. T cell-mediated host immune defenses in the lung. Annu Rev Immunol 2013;31:605–633.
32. Parker D, Ahn D, Cohen T, Prince A. Innate immune signaling activated by MDR bacteria in the airway. Physiol Rev 2016;96:19–53.
33. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol 2016;16:51–67.
34. Abdulnour RE, Sham HP, Douda DN, Colas RA, Dalli J, Bai Y, et al. Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation. Mucosal Immunol 2016;9:1278–1287.
35. Coleman FT, Blahna MT, Kamata H, Yamamoto K, Zabinski MC, Kramnik I, et al. Capacity of pneumococci to activate macrophage nuclear factor kB: influence on necroptosis and pneumonia severity. J Infect Dis 2017;216:425–435.
36. Kamata H, Yamamoto K, Wasserman GA, Zabinski MC, Yuen CK, Lung WY, et al. Epithelial cell–derived secreted and transmembrane 1a signals to activated neutrophils during pneumococcal pneumonia. Am J Respir Cell Mol Biol 2016;55:407–418.
37. Parker D, Planet PJ, Soong G, Narechania A, Prince A. Induction of type I interferon signaling determines the relative pathogenicity of Staphylococcus aureus strains. PLoS Pathog 2014;10:e1003951.
38. Kitur K, Parker D, Nieto P, Ahn DS, Cohen TS, Chung S, et al. Toxin-induced necroptosis is a major mechanism of Staphylococcus aureus lung damage. PLoS Pathog 2015;11:e1004820.
39. Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol 2017;10:299–306.
40. Twigg HL III, Knox KS, Zhou J, Crothers KA, Nelson DE, Toh E, et al. Effect of advanced HIV infection on the respiratory microbiome. Am J Respir Crit Care Med 2016;194:226–235.
41. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrançois L, Farber DL. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 2011;187:5510–5514.
42. Smith NM, Wasserman GA, Coleman FT, Hilliard KL, Yamamoto K, Lipsitz E, et al. Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia. Mucosal Immunol 2018;11:220–235.
43. Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA, et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 2016;532:512–516.
44. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. Science 2016;352:aaf1098.
45. Holcomb ZE, Tsalik EL, Woods CW, McClain MT. Host-based peripheral blood gene expression analysis for diagnosis of infectious diseases. J Clin Microbiol 2017;55:360–368.
46. Tsalik EL, Henao R, Nichols M, Burke T, Ko ER, McClain MT, et al. Host gene expression classifiers diagnose acute respiratory illness etiology. Sci Transl Med 2016;8:322ra11.
47. Sweeney TE, Khatri P. Generalizable biomarkers in critical care: toward precision medicine. Crit Care Med 2017;45:934–939.
48. Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. Sci Transl Med 2016;8:346ra91.
49. Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Anzueto A, Babu BL, et al. Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling. Am J Respir Crit Care Med 2017;196:609–620.
50. Barreiro E, Sznajder JI, Nader GA, Budinger GR. Muscle dysfunction in patients with lung diseases: a growing epidemic. Am J Respir Crit Care Med 2015;191:616–619.
51. Budinger GRS, Kohanski RA, Gan W, Kobor MS, Amaral LA, Armanios M, et al. The intersection of aging biology and the pathobiology of lung diseases: a joint NHLBI/NIA workshop. J Gerontol A Biol Sci Med Sci 2017;72:1492–1500.
52. Mayr FB, Talisa VB, Balakumar V, Chang CH, Fine M, Yende S. Proportion and cost of unplanned 30-day readmissions after sepsis compared with other medical conditions. JAMA 2017;317:530–531.
53. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313:264–274.
54. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004;169:910–914.
55. Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, et al.; GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008;177:1242–1247.
56. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al.; PRORATA trial group. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463–474.
57. Yende S, D’Angelo G, Mayr F, Kellum JA, Weissfeld L, Kaynar AM, et al.; GenIMS Investigators. Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deaths. PLoS One 2011;6:e22847.
58. Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med 2014;2:238–246.
59. Wang J, Lesko M, Badri MH, Kapoor BC, Wu BG, Li Y, et al. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-g. ERJ Open Res 2017;3:00008-2017.
60. Fastrès A, Felice F, Roels E, Moermans C, Corhay JL, Bureau F, et al. The lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies. Int J Mol Sci 2017;18:2735.
61. Green H, Jones AM. The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med 2015;36:225–235.
62. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 2014;146:1187–1195.
63. Rangelov K, Sethi S. Role of infections. Clin Chest Med 2014;35:87–100.
64. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med 2009;30:3–9.
65. Singanayagam A, Chalmers JD. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med 2013;1:653–662.
66. Bermejo-Martin JF, Almansa R, Martin-Fernandez M, Menendez R, Torres A. Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. Lancet Respir Med 2017;5:e35–e36.
67. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677–686.
68. Cleaver JO, You D, Michaud DR, Pruneda FA, Juarez MM, Zhang J, et al. Lung epithelial cells are essential effectors of inducible resistance to pneumonia. Mucosal Immunol 2014;7:78–88.
69. Morley D, Torres A, Cillóniz C, Martin-Loeches I. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. Ann Transl Med 2017;5:443.
70. Yende S, Tuomanen EI, Wunderink R, Kanaya A, Newman AB, Harris T, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med 2005;172:1440–1446.
71. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al.; GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007;167:1655–1663.